TRANSCENTA-B News

Chuangsheng Group-B (6628.HK): Phase I/II clinical data shows that TST001 triple therapy is expected to improve first-line treatment for patients with gastric or gastroesophageal conjunctional adenocarcinoma

Jun 4, 2024 00:00

Chuangsheng Group-B (6628.HK) immediate review: second-generation CLDN18.2 antibody clinical data are excellent

國元國際Jul 3, 2023 00:00

Chuangsheng Group-B (6628.HK): Clinical data is impressive, second-generation CLDN18.2 antibody development progress is first in China, second in the world

國元國際Dec 12, 2022 00:00

Chuangsheng Group (06628.HK): Innovative drug star with full-platform capabilities for biopharmaceutical R&D, clinical and production

興業證券Oct 3, 2021 00:00

Chuangsheng Group (6628.HK) IPO Report: Rating: 69 Rating: Neutral

中泰國際Sep 14, 2021 00:00

Chuangsheng Group Pharmaceutical Co., Ltd. - B (6628.HK): IPO News

致富證券Sep 14, 2021 00:00